Approximately 80%–90% of patients with biochemically‐confirmed OTC deficiency have a disease‐causing variant identified,5 largely within the coding region or intron/exon boundaries of the OTC gene. Here, OTC is linked to ornithine carbamoyltransferase deficiency.